Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Clin Cancer Res. 2016 Mar 1;22(5):1037–1047. doi: 10.1158/1078-0432.CCR-15-0905

TABLE 2.

JAK inhibitors in clinical development for MF

Drug Target Off-targets Phase Current status
Momelotinib (CYT387)
graphic file with name nihms744037t1.jpg 		JAK1, JAK2 TYK2 3 Recruiting
Pacritinib (SB1518)
graphic file with name nihms744037t2.jpg 		JAK2 FLT3 3 PERSIST-2 recruiting
NS-018
graphic file with name nihms744037t3.jpg 		JAK2 Src family 1/2 Recruiting
Fedratinib (SAR302503)
graphic file with name nihms744037t4.jpg 		JAK2 FLT3, RET 3 Drug development terminated due to adverse neurologic sequelae, including Wernicke’s encephalopathy
AZD1480
graphic file with name nihms744037t5.jpg 		JAK1, JAK2 1 Study terminated following observed low-grade neurological toxicity
Lestaurtinib (CEP701)
graphic file with name nihms744037t6.jpg 		JAK2 FLT3, TrkA 2 Phased out of development in MF due to unacceptable GI toxicity and narrow therapeutic window
BMS-911543
graphic file with name nihms744037t7.jpg 		JAK2 1/2 No longer in clinical development for MF due to high rate of drug discontinuation rate and questionable efficacy
Gandotinib (LY2784544)
graphic file with name nihms744037t8.jpg 		JAK2 2 No longer in clinical development for MF; high rate of renal insufficiency, tumor lysis
INCB039110
graphic file with name nihms744037t9.jpg 		JAK1 2 No longer in clinical development for MF